Aspira Women's Health Narrows Losses Amidst Cost Cuts

Ticker: AWHL · Form: 10-Q · Filed: Aug 13, 2025 · CIK: 926617

Sentiment: mixed

Topics: Biotechnology, Diagnostics, Going Concern, Liquidity Risk, Net Loss, Cost Reduction, Equity Dilution

TL;DR

**AWHL is still bleeding cash, but cost cuts are slowing the burn; watch for dilution as they scramble for capital.**

AI Summary

Aspira Women's Health Inc. (AWHL) reported a net loss of $2.666 million for the three months ended June 30, 2025, an improvement from the $3.530 million net loss in the same period of 2024. For the six months ended June 30, 2025, the net loss was $4.519 million, significantly better than the $8.159 million loss in the prior year. Total revenue for the three months ended June 30, 2025, was $2.404 million, a slight decrease from $2.423 million in 2024, while six-month revenue increased to $4.683 million from $4.576 million. Gross profit rose to $1.534 million for the quarter and $3.094 million for the six months, up from $1.421 million and $2.635 million, respectively, in 2024. Operating expenses saw a substantial reduction, falling to $3.344 million for the quarter from $5.814 million, and to $8.144 million for the six months from $11.738 million, primarily due to decreased sales and marketing expenses. The company's cash and cash equivalents stood at $1.545 million as of June 30, 2025, down from $1.769 million at December 31, 2024, and it continues to operate with a working capital deficit of $412,000. The company raised $3.484 million from its 2024 At-the-Market Offering Agreement and $1.366 million from Convertible Notes during the six months ended June 30, 2025, to support liquidity.

Why It Matters

Aspira's ability to significantly reduce its net loss and operating expenses, particularly in sales and marketing, suggests a more disciplined approach to its business model, which could be a positive signal for investors. However, the persistent working capital deficit of $412,000 and the 'substantial doubt' about its going concern status highlight ongoing financial fragility. For employees, continued cost-cutting measures could imply job insecurity or reduced compensation. Customers might see a more focused product offering, but the company's financial instability could raise questions about long-term support for its diagnostic tests like OvaSuite. In a competitive diagnostics market, Aspira's struggle for profitability makes it vulnerable to larger, better-capitalized players.

Risk Assessment

Risk Level: high — Aspira Women's Health Inc. faces a high risk level due to its 'substantial doubt' about continuing as a going concern, as explicitly stated in the filing. The company reported an accumulated deficit of $535.916 million and a working capital deficit of $412,000 as of June 30, 2025, alongside a net loss of $4.519 million and $4.836 million in cash used in operations for the six months ended June 30, 2025.

Analyst Insight

Investors should exercise extreme caution and consider avoiding AWHL stock given the explicit 'going concern' warning and persistent negative cash flow. Those already invested should closely monitor any further equity offerings, as significant dilution is a stated risk, and evaluate the company's ability to secure additional financing on favorable terms.

Financial Highlights

debt To Equity
N/A
revenue
$4.683M
operating Margin
-107.81%
total Assets
$4.934M
total Debt
$2.532M
net Income
$ -4.519M
eps
$ -0.16
gross Margin
66.07%
cash Position
$1.545M
revenue Growth
2.34%

Revenue Breakdown

SegmentRevenueGrowth
Product Revenue$2.404M-0.78%

Key Numbers

Key Players & Entities

FAQ

What is Aspira Women's Health Inc.'s current financial liquidity position?

As of June 30, 2025, Aspira Women's Health Inc. had $1.545 million in cash and cash equivalents. The company also reported a working capital deficit of $412,000, indicating short-term liabilities exceed current assets.

How has Aspira Women's Health Inc.'s net loss changed year-over-year?

For the six months ended June 30, 2025, Aspira Women's Health Inc. reported a net loss of $4.519 million, a significant improvement compared to the $8.159 million net loss for the same period in 2024.

What are the primary risks to Aspira Women's Health Inc. investors?

The primary risks include 'substantial doubt' about the company's ability to continue as a going concern, persistent negative cash flows from operations ($4.836 million used in H1 2025), and potential significant dilution from future equity offerings needed to raise capital.

What strategies is Aspira Women's Health Inc. pursuing to improve its financial position?

Aspira Women's Health Inc. plans to raise capital through equity offerings or debt, reduce executive bonuses, replace cash compensation with equity, cut professional services and consulting fees, eliminate non-critical projects, and reduce discretionary marketing programs.

How much revenue did Aspira Women's Health Inc. generate in the last quarter?

For the three months ended June 30, 2025, Aspira Women's Health Inc. generated $2.404 million in total product revenue, a slight decrease from $2.423 million in the same quarter of 2024.

What is the significance of the 'going concern' disclosure for Aspira Women's Health Inc.?

The 'going concern' disclosure indicates that management has significant doubts about Aspira Women's Health Inc.'s ability to meet its financial obligations over the next year without further capital raises or operational changes, signaling high financial instability.

How have Aspira Women's Health Inc.'s operating expenses changed?

Operating expenses for Aspira Women's Health Inc. decreased substantially to $3.344 million for the three months ended June 30, 2025, from $5.814 million in the prior year, and to $8.144 million for the six months from $11.738 million, primarily driven by reduced sales and marketing costs.

What products does Aspira Women's Health Inc. currently market?

Aspira Women's Health Inc. markets the Ova1Plus workflow (using Ova1 and Overa) and OvaWatch, which are diagnostic tests for gynecologic disease, collectively referred to as OvaSuite.

What was the impact of warrant liabilities on Aspira Women's Health Inc.'s financials?

The change in fair value of warrant liabilities resulted in a $624,000 expense for the three months ended June 30, 2025, compared to an $889,000 income in the prior year, and a $297,000 income for the six months ended June 30, 2025, compared to $1.140 million income in the prior year.

How many shares of common stock does Aspira Women's Health Inc. have outstanding?

As of August 8, 2025, Aspira Women's Health Inc. had 35,655,918 shares of common stock outstanding, which is a significant increase from 17,407,120 shares outstanding at December 31, 2024, indicating substantial dilution.

Risk Factors

Industry Context

Aspira Women's Health operates in the women's health diagnostics sector, a growing but competitive market. The industry is characterized by innovation in genetic testing, early disease detection, and personalized medicine. Companies in this space often face challenges related to regulatory approvals, reimbursement policies, and the need for significant R&D investment to stay competitive.

Regulatory Implications

As a healthcare diagnostics company, Aspira Women's Health is subject to stringent regulatory oversight from bodies like the FDA for its diagnostic tests. Compliance with CLIA (Clinical Laboratory Improvement Amendments) regulations is also critical for laboratory operations. Changes in healthcare policy or reimbursement rates from payers like Medicare and private insurers can significantly impact revenue and profitability.

What Investors Should Do

  1. Monitor cash burn rate and runway: With $1.545 million in cash and a working capital deficit, investors should closely track the company's ability to manage its cash flow and operations without requiring immediate further financing.
  2. Evaluate progress on revenue growth: The slight decline in Q2 revenue warrants attention. Investors should look for signs of stabilization or growth in product revenue in future filings.
  3. Assess cost control effectiveness: While operating expenses have been reduced, the company's ability to achieve profitability hinges on sustained cost management and revenue generation.
  4. Understand dilution impact: The company has issued new shares through ATM offerings and convertible notes. Investors should monitor the outstanding share count and potential for future dilution.
  5. Analyze the path to profitability: Given the substantial accumulated deficit, investors need to see a clear strategy and execution plan for achieving sustainable profitability.

Key Dates

Glossary

At-the-Market Offering Agreement
A type of equity offering where a company sells shares of its stock on a stock exchange at prevailing market prices. This allows for flexible capital raising. (The company raised $3.484 million through this agreement in 2024, contributing to its liquidity.)
Convertible Notes
Debt securities that can be converted into a predetermined amount of the issuer's equity (common stock) at certain times or under certain conditions. (The company raised $1.366 million from convertible notes and also experienced a loss upon issuance of convertible notes carried at fair value, impacting its financial statements.)
Working Capital Deficit
A situation where a company's current liabilities exceed its current assets. It can indicate short-term liquidity issues. (Aspira Women's Health Inc. reported a working capital deficit of $412,000 as of June 30, 2025.)
Accumulated Deficit
The cumulative net losses of a company since its inception that have not been offset by net income. It represents a negative retained earnings balance. (The company has a significant accumulated deficit of $535.916 million as of June 30, 2025, reflecting its history of losses.)
Warrant Liabilities
Liabilities arising from warrants issued by the company that give the holder the right, but not the obligation, to purchase shares of the company's stock at a specified price. These are typically revalued each reporting period. (The company reported a change in fair value of warrant liabilities, which impacted its 'Other (expense) income, net'.)
Stock-based compensation expense
The cost recognized by a company for equity awards granted to employees and directors, such as stock options or restricted stock units. (This non-cash expense is adjusted for in the cash flow statement and impacts net loss.)

Year-Over-Year Comparison

Compared to the prior year's six-month period, Aspira Women's Health has significantly reduced its net loss from $8.159 million to $4.519 million, and cash used in operations has decreased from $8.172 million to $4.836 million. This indicates improved operational efficiency and cost control, particularly in sales and marketing expenses which saw a substantial reduction. However, revenue has seen a slight dip in the most recent quarter, and the company continues to operate with a working capital deficit and a substantial accumulated deficit, highlighting ongoing financial challenges despite the positive trends in loss reduction.

Filing Stats: 4,594 words · 18 min read · ~15 pages · Grade level 17.9 · Accepted 2025-08-12 18:12:09

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES 40 The following are registered and unregistered trademarks and service marks of Aspira Women's Health Inc.: VERMILLION SM , Aspira Women's Health , OVA1 , OVERA , ASPiRA LABS , OvaCalc , OVASUITE SM , ASPiRA GenetiX SM , OVA1PLUS , OVAWATCH , EndoCheck SM , ENDOINFORM TM , OVAINFORM TM , OVAInherit SM , Aspira Synergy , OVA360 SM , ASPIRA IVD SM , and YOUR HEALTH, OUR PASSION . i PART I - FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS Aspira Women's Health Inc. Condensed Consolidated Balance Sheets (unaudited) (Amounts in Thousands, Except Share and Par Value Amounts) June 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 1,545 $ 1,769 Accounts receivable, net of reserves of $ 0 1,278 990 Prepaid expenses and other current assets 590 1,098 Inventories 273 326 Total current assets 3,686 4,183 Property and equipment, net 44 69 Right-of-use assets 1,077 1,194 Other assets 127 45 Total assets $ 4,934 $ 5,491 Liabilities and Stockholders' Deficit Current liabilities: Accounts payable $ 1,743 $ 2,173 Accrued liabilities 1,829 2,445 Current portion of long-term debt 232 229 Short-term debt 154 614 Current maturities of lease liabilities 140 7 Total current liabilities 4,098 5,468 Non-current liabilities: Long-term debt 1,160 1,278 Non-current maturities of lease liabilities 1,121 1,248 Warrant liabilities 1,240 60 Total liabilities 7,619 8,054 Commitments and contingencies (Note 4) - - Stockholders' deficit: Common stock, par value $ 0.001 per share, 200,000,000 and 200,000,000 shares authorized at June 30, 2025 and December 31, 2024, respectively; 35,637,325 and 17,407,120 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 36 17 Additional paid-in capital 533,195 528,817 Accumulated deficit ( 535,916 ) ( 531,397 ) Total stockholders' deficit ( 2,685 ) ( 2,563 ) Total

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing